Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Fruman

Showing results (21-30 of 105) with videos related to

Pageof 11
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|June 10, 2003
Proliferation and survival of activated B cells requires sustained antigen receptor engagement and phosphoinositide 3-kinase activationAmber C Donahue, David A Fruman
Science Signaling|April 23, 2009
Immune regulation by rapamycin: moving beyond T cellsMatthew R Janes, David A Fruman
Methods in Molecular Biology (Clifton, N.J.)|November 30, 2011
The in vivo evaluation of active-site TOR inhibitors in models of BCR-ABL+ leukemiaMatthew R Janes, David A Fruman
European Journal of Immunology|August 29, 2007
Distinct signaling mechanisms activate the target of rapamycin in response to different B-cell stimuliAmber C Donahue, David A Fruman
Cancer Research|March 23, 2005
ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectorsMichael G Kharas, David A Fruman
The Journal of Clinical Investigation|August 19, 2014
Too much of a good thing: immunodeficiency due to hyperactive PI3K signalingCraig M Walsh, David A Fruman
Frontiers in Immunology|August 14, 2012
Akt and mTOR in B Cell Activation and DifferentiationJose J Limon, David A Fruman
Cancer Discovery|July 9, 2015
INPP4B Is a Tumor Suppressor in the Context of PTEN DeficiencyThanh-Trang T Vo, David A Fruman
Frontiers in Oncology|May 1, 2023
Novel pharmacological and dietary approaches to target mTOR in B-cell acute lymphoblastic leukemiaRoberta Buono, Muneera Alhaddad, David A Fruman
Molecular Cell|June 7, 2024
The picky mTORC1 in metabolic enzyme degradationYujin Chun, David A Fruman, Gina Lee
Pageof 11

Showing results (21-30 of 105) with videos related to

Sort By:
Pageof 11
Journal of Immunology (Baltimore, Md. : 1950)|June 10, 2003
Proliferation and survival of activated B cells requires sustained antigen receptor engagement and phosphoinositide 3-kinase activationAmber C Donahue, David A Fruman
Science Signaling|April 23, 2009
Immune regulation by rapamycin: moving beyond T cellsMatthew R Janes, David A Fruman
Methods in Molecular Biology (Clifton, N.J.)|November 30, 2011
The in vivo evaluation of active-site TOR inhibitors in models of BCR-ABL+ leukemiaMatthew R Janes, David A Fruman
European Journal of Immunology|August 29, 2007
Distinct signaling mechanisms activate the target of rapamycin in response to different B-cell stimuliAmber C Donahue, David A Fruman
Cancer Research|March 23, 2005
ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectorsMichael G Kharas, David A Fruman
The Journal of Clinical Investigation|August 19, 2014
Too much of a good thing: immunodeficiency due to hyperactive PI3K signalingCraig M Walsh, David A Fruman
Frontiers in Immunology|August 14, 2012
Akt and mTOR in B Cell Activation and DifferentiationJose J Limon, David A Fruman
Cancer Discovery|July 9, 2015
INPP4B Is a Tumor Suppressor in the Context of PTEN DeficiencyThanh-Trang T Vo, David A Fruman
Frontiers in Oncology|May 1, 2023
Novel pharmacological and dietary approaches to target mTOR in B-cell acute lymphoblastic leukemiaRoberta Buono, Muneera Alhaddad, David A Fruman
Molecular Cell|June 7, 2024
The picky mTORC1 in metabolic enzyme degradationYujin Chun, David A Fruman, Gina Lee
Pageof 11